314 results about "High titer" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention relates to the technical field of molecular biology, in particular to an avian adenovirus serum type 4 colloidal gold test strip based on a monoclonal antibody and application of the test strip. According to the invention, two monoclonal antibodies (6B3 and 8G11) aiming at FAdV4 penton protein are successfully prepared through a hybridoma technology, and both the monoclonal antibodies show high titer and strong serotype specificity. Specific analysis proves that the two monoclonal antibodies can recognize 12 FAdV4 isolates from different sources, and do not have cross reaction with other FAdV serotypes or common poultry pathogens. According to the invention, through systematic optimization of key parameters, the detection sensitivity of the test strip is 7.81 * 10 < 4 > TCID50 / 0.1 mL, and the detection time is only 15 minutes. Clinical sample verification shows that compared with an ELISA method, the total coincidence rate is 98.6%.

The invention discloses an anti-dsDNA antibody or an antigen binding fragment thereof, a detection reagent and a kit, and relates to the technical field of biological detection. The anti-dsDNA antibody or the antigen binding fragment thereof provided by the invention comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO. 1; the amino acid sequence of the light chain variable region is as shown in SEQ ID NO. 2. The detection reagent provided by the invention comprises the anti-dsDNA antibody or the antigen binding fragment thereof. The anti-dsDNA antibody or the antigen binding fragment thereof provided by the invention solves the problems of traceability of positive blood and large-scale supply. By applying the scheme of the invention, the anti-dsDNA with high titer, high accuracy and good stability or the antigen binding fragment thereof can be prepared, and a raw material source with excellent performance is provided for the preparation of a calibration product / a positive control product / a quality control product of an anti-dsDNA detection kit.

The invention belongs to the technical field of biochemical engineering, and particularly relates to an amitriptyline hapten and a preparation method thereof, an amitriptyline antigen and a preparation method thereof, an antibody, a kit and application. The amitriptyline hapten has a structural formula shown as a formula (I) or a formula (II). Compared with an existing structure, the amitriptyline hapten prepared by the invention has a better immune effect. The obtained antibody is high in titer, strong in specificity and high in affinity, the LOD of amitriptyline by using an Elisa method established by the antibody is 0.013 ng / mL, the IC50 of amitriptyline is 0.865 ng / mL, the quantitative detection range is 0.07-470.3 ng / mL, the detection sensitivity is high, and the linear range is wide.

The invention relates to the technical field of immune carrier microspheres, in particular to an immune carrier microsphere constructed by individualized MHC-II combined polypeptide, a vaccine and application of the immune carrier microsphere and the vaccine. A core comprises microspheres constructed by a plurality of MHC-II binding polypeptides, sequences of the MHC-II binding polypeptides are obtained based on HLA gene typing results of an inoculator, and each HLA gene corresponds to at least one high-affinity MHC-II binding polypeptide; a shell is a glucan with sulfydryl or other polymer coating layer, and sulfydryl is used as a coupling group to be connected with an antigen to construct the vaccine. The method has the advantages that competition is avoided, inhibition is generated, a better immune effect is achieved, antibodies of high-titer carrier molecules are not generated, and cross reaction side effects are avoided. The carrier molecular diversity is reduced; side effects are avoided. And antibody immunity and cellular immunity functions are generated. The particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants. The preparation process is simple to operate and good in repeatability.

A specific protein fragment capable of representing salmonella as an antigen is obtained through screening and experimental verification, a mouse is immunized with the specific protein fragment as the antigen, and hybridoma cells capable of stably secreting monoclonal antibodies are obtained through a cell fusion technology. And finally, the anti-salmonella monoclonal antibody with high titer and good specificity is prepared. Similarly, the specific protein fragment is used for immunizing a rabbit to obtain the anti-salmonella polyclonal antibody. On the basis of a mouse monoclonal antibody and a rabbit polyclonal antibody, a salmonella colloidal gold immunochromatography detection method is established, the detection method is good in specificity, and a rapid, simple and convenient detection means is provided for detection of salmonella in food.

The invention discloses an mRNA-LNPs Brucella vaccine, an expression vector and a preparation method thereof. The mRNA-LNPs Brucella vaccine comprises at least one of mRNA of an outer membrane protein BP26 and mRNA of an outer membrane protein Omp 25. According to the present invention, the antigen sequence is optimized, the prepared mRNA Brucella vaccine can stimulate the body to produce strong immunogenicity, and compared with the Brucella vaccine prepared before the sequence optimization, the antibody titer is significantly improved. A mouse immune experiment research result shows that high-titer IgG, IgG1 and IgG2a can be generated. Th1 type reaction, Th2 type reaction or mixed Th type reaction is successfully induced.

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.

The invention discloses chicken infectious anemia virus-like particles as well as a preparation method and application thereof. The invention discloses a virus-like particle vaccine for preventing chicken infectious anemia. The virus-like particle vaccine comprises VP1 and VP2 proteins of chicken infectious anemia viruses. Chicken infectious anemia VP1 and VP2 proteins are expressed by using a baculovirus expression system, immunoblotting shows that the two proteins are successfully expressed in sf9 cells, electron microscope observation finds that the expressed proteins can be autonomously assembled into complete chicken infectious anemia virus-like particles, and the chicken infectious anemia virus-like particles have a space structure similar to that of an original virus and can be used for preparing chicken infectious anemia virus-like particles. Meanwhile, the virus-like particles have the advantages of high titer, high safety, capability of stimulating humoral immunity and cellular immunity and the like. The preparation method disclosed by the invention is simple, can be used for preparing the antigen protein of the chicken infectious anemia virus on a large scale, is high in expression quantity and short in time consumption, greatly reduces the production cost, and is suitable for large-scale production.

The invention discloses prokaryotic expression and purification of Echinococcus multilocularis glutathione S-transferase, and preparation and application of a polyclonal antibody, and relates to the technical field of biology.The technical key point is that the preparation method of the polyclonal antibody of the Echinococcus multilocularis glutathione S-transferase comprises the following steps that S1, RNA in vesicle tissue of Echinococcus multilocularis is extracted, and cDNA is prepared; s2, carrying out PCR (Polymerase Chain Reaction) amplification by taking the cDNA as a template to obtain an EmGST gene which can encode an amino acid sequence as shown in SEQ ID NO: 1; s3, connecting the EmGST gene to a prokaryotic expression vector plasmid through a double digestion enzyme reaction to construct a recombinant vector, then transfecting the recombinant vector to competent escherichia coli, and inducing prokaryotic expression and purification to obtain a recombinant protein; and S4, immunizing a mouse to prepare antiserum by taking the echinococcosis multilocularis glutathione transferase as an antigen, and purifying the antiserum to obtain the polyclonal antibody of the echinococcosis multilocularis glutathione transferase. The ImGST protein polyclonal antibody prepared by the invention has the advantages of high titer and good specificity.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.

The invention relates to the technical field of antibodies, in particular to an anti-African swine fever virus p30 protein monoclonal antibody and application thereof, and the anti-African swine fever virus p30 protein monoclonal antibody can be specifically combined with African swine fever virus p30 protein. The anti-ASFV p30 protein monoclonal antibody is prepared by immunizing a BALB / c mouse through an immunological method, and the antibody is high in specificity, titer and affinity and can be applied to immunological detection or antibody detection kits.

The invention discloses a hybridoma cell strain secreting an anti-micro-nano plastic monoclonal antibody and application thereof.The hybridoma cell strain comprises a hybridoma cell strain MP-4 and a hybridoma cell strain MP-9, the hybridoma cell strain MP-4 and the hybridoma cell strain MP-9 are obtained through self screening of the inventor, the preservation number of the hybridoma cell strain MP-4 is CCTCC NO: C2024262, the preservation number of the hybridoma cell strain MP-9 is CCTCC NO: C2024262, and the preservation number of the hybridoma cell strain MP-9 is CCTCC NO: C2024262. The preservation number of the hybridoma cell strain MP-9 is CCTCC NO: C2024261. The passage cell strain of the hybridoma cell provided by the invention can stably secrete an anti-broad-spectrum micro-nano plastic protein monoclonal antibody, the secreted antibody has high titer and good sensitivity, can simultaneously recognize PS, PVC, PP, PE and PET, has good broad-spectrum recognizability, provides a core raw material for establishing a broad-spectrum immunodetection method of micro-plastics, and has good application prospects. Wide application prospects are realized.

The invention belongs to the technical field of biological medicine, particularly relates to an Alzheimer's disease protein marker, an antibody diagnostic kit and application of the antibody diagnostic kit, and provides the Alzheimer's disease protein marker A beta (1-42). The invention provides a kit for detecting human amyloid A beta based on sandwich ELISA (enzyme-linked immunosorbent assay) of 2B6 and 3A8 antibodies, and further provides a kit for detecting human amyloid A beta based on 2B6 and 3A8 antibodies by predicting B cell epitopes of a template A beta (1-42) protein through ABCpred to reconstruct an immune antigen enhanced Alzheimer disease combined antigen such as SEQ ID NO: 1, called AD-A beta 2 for short, and monoclonal antibodies 2B6 and 3A8 with strong affinity and high titer based on the antigen. The A beta concentration detection line effect of at least 0.5 ng / mL is realized.

The invention belongs to the technical field of immunodetection, and discloses a hapten and an artificial antigen for sulfonamide drug detection, a construction method and an application thereof, the structure of the hapten and the artificial antigen is shown as a formula (1): R1 =-COOH, R2 = R3 = H; r2 =-COOH, R1 = R3 = H; r3 is-COOH, and R1 is equal to R2 and H is equal to H. The invention discloses a novel sulfonamide immune hapten and a construction method of an artificial antigen of the novel sulfonamide immune hapten for the first time, and successfully obtains a specific antibody with high titer, high sensitivity and broad-spectrum recognition capability on the basis of immune animals of the artificial antigen.

The invention discloses an anti-CD3D antibody and application thereof.The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of CDR-H1 of the heavy chain variable region is shown as SEQ ID NO: 4, the amino acid sequence of CDR-H2 of the heavy chain variable region is shown as SEQ ID NO: 5, and the amino acid sequence of CDR-H3 of the heavy chain variable region is GDL; the amino acid sequence of the CDR-L1 of the light chain variable region is as shown in SEQ ID NO: 6, the amino acid sequence of the CDR-L2 of the light chain variable region is as shown in SEQ ID NO: 7, and the amino acid sequence of the CDR-L3 of the light chain variable region is as shown in SEQ ID NO: 8. The anti-CD3D antibody is a rabbit monoclonal antibody, the obtained antibody is high in titer, clear in specific positioning in immunohistochemical staining and free of non-specific background staining, the antibody is wide in application, and the antibody can be used in pathological immunohistochemical staining experiments and can also be used in Western blot and flow cytometry experiments.

Provided are a fully human TSH receptor (TSHR) blocking monoclonal antibody for treating hyperthyroidism, and a preparation method therefor and a use thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and memory single B cells specifically recognizing a TSHR in the peripheral blood of patients having high titers of TSHR blocking antibody (TSH-stimulating blocking antibody, TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells for antibody property screening and validation, to obtain a blocking monoclonal antibody specifically targeting human TSHR. The fully human TSHR blocking monoclonal antibody can specifically bind to the TSHR, has good inhibitory activity in vitro and in vivo experiments, and has broad application prospects in the development of treatment of Graves' diseases.

The invention discloses an allergen specific IgE and IgG antibody composite quality control product or calibration product as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The preparation method comprises the following steps: obtaining a whole-genome sequence comprising a human IgE constant region gene sequence, a human IgG4 constant region gene sequence and a human IgG1 constant region gene sequence, and preparing a fusion protein simultaneously containing a human IgE Fc segment and a human IgG Fc segment; immunizing a healthy animal by using the allergen to obtain a purified antibody; and carrying out chemical coupling on the purified antibody and the fusion protein to obtain allergen specific IgE and IgG antibodies. By constructing allergen specific IgE and IgG antibodies, the kit can be simultaneously applied to detection of allergens IgE and IgG, has the advantages of high titer, high purity, good dilution linearity and the like, and is beneficial to improvement of diagnosis accuracy and treatment effectiveness.

The invention discloses a group of blocking monoclonal antibodies of an SH1 homologous cluster fully human thyrotropin receptor (TSHR) (a TSH receptor, TSHR) as well as a preparation method and application of the blocking monoclonal antibodies of the SH1 homologous cluster fully human thyrotropin receptor (TSHR). The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH receptor blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; expression and fibrosis of effector cell orbital fibroblasts TSHR for inhibiting thyroid-related eye diseases are remarkably relieved, and wide application prospects are achieved in treatment of Graves' diseases and diseases such as thyroid eye diseases caused by hyperthyroidism.

The present invention relates to the technical field of biomedicine. Provided are a rabies virus G protein mutant, and a preparation method therefor and the use thereof. The rabies virus G protein mutant is obtained by means of a site mutation on the extracellular domain of a G protein. For the mutant, soluble expression of the extracellular domain of the G protein is realized, and the mutant can induce the generation of a neutralizing antibody with a high titer. Compared with commercial rabies vaccines for human and rabies vaccines for dogs, the mutant has better cell immune and antibody immune responses. The mutant is expected to reduce the inoculation frequency, shorten the immunizing procedure, and decrease the immunizing dose.

The invention relates to the technical field of antibodies, in particular to antigen peptides of human PP1 alpha protein and Thr320 site phosphorylated protein of the human PP1 alpha protein, and a preparation method and application of an antibody of the antigen peptides of the human PP1 alpha protein and the Thr320 site phosphorylated protein. The invention provides an antigen peptide of human PP1 alpha protein and Thr320 site phosphorylated protein thereof, the antigen peptide has obvious advantages in the aspects of immunogenicity and the like, animals can be induced to generate high-level antibodies, and the generated antibodies have high specificity, affinity and titer. Based on the antigen peptide, the invention provides an anti-human PP1 alpha protein or a polyclonal antibody with phosphorylated Thr320 site thereof and a preparation method thereof, the polyclonal antibody has the characteristics of strong specificity, high affinity and high titer, and through immunoblotting and immunohistochemical verification, the polyclonal antibody can be used for preparing the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein or the anti-human PP1 alpha protein. The probe shows good specificity and sensitivity in detection of phosphorylation modification of human PP1 alpha protein and Thr320 site thereof, and has a good application prospect.

The invention discloses a group of blocking monoclonal antibodies of a CHK36 homologous cluster fully human TSH receptor (TSHR) as well as a preparation method and application of the blocking monoclonal antibodies. The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH-blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells, so as to obtain the TSHR-TBAb-TSHR-TBAb. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; according to the present invention, with the application of the compound, the expression and the fibrosis of the effector cell orbit fibroblast TSHR inhibiting the thyroid-related eye disease can be significantly reduced, and the wide application prospect is provided in the treatment of Graves' disease (Graves' disease, GD) and diseases caused by hyperthyroidism, such as thyroid eye disease (thyroid eye disease, TED), and the like.

The present invention discloses mutants of wild-type RSV F protein. The binding experiment of pre-fusion conformation trimer-specific monoclonal antibody AM14 shows that the mutant provided in the embodiment of the present disclosure can have strong binding activity with AM14 monoclonal antibody, while the wild-type RSV F protein before artificial mutation has no binding activity with AM14 monoclonal antibody. The results of accelerated stability test show that the mutant provided in the embodiment of the present disclosure is placed in a 37°C environment for 4 weeks, and the binding activity of AM14 monoclonal antibody has no obvious change. The results of animal immunization experiments show that compared with the wild-type RSV F protein before artificial mutation, the mutant provided in the embodiment of the present disclosure can induce the production of higher titers of neutralizing antibodies.

The invention provides an analgin hapten, a preparation method thereof, an artificial antigen, an antibody and application. The structures of the analgin haptens are as shown in a formula (I) or a formula (II), the two analgin haptens provided by the invention have spacer arms with proper lengths, and after the two analgin haptens are coupled with protein, the haptens can be fully exposed to an immune system, the spacer arms can be prevented from being recognized as much as possible, and a better antibody is generated to recognize analgin. The analgin hapten is used for preparing artificial antigen and antibody, the obtained analgin monoclonal antibody has high titer and strong specificity, an immunoassay method constructed based on the analgin monoclonal antibody has high specificity and sensitivity, analgin in a sample can be rapidly, qualitatively and quantitatively detected, the operation is simple and convenient, and the detection result is accurate and reliable.

Prokaryotic expression of a cat allergen protein chimeric peptide cFel d 1 based on a T-cell antigen epitope, and preparation of an egg yolk antibody. A chimeric peptide cFel d 1, comprising a 25-41th-position amino acid residue segment, a 46-59th-position amino acid residue segment, a 85-98th-position amino acid residue segment, a 132-140th-position amino acid residue segment and a 145-153th-position amino acid residue segment of a cat allergen Fel d 1 antigen amino acid residue. Experiments prove that an antibody obtained after immunizing animals by means of the chimeric peptide cFel d 1 has high titer, can specifically bind to a cat allergen complete Fel d 1 protein, and is superior to a polyclonal antibody prepared by means of a complete Fel d 1 protein (the titer is 8 times higher).

This invention discloses a hybridoma cell line that secretes anti-polystyrene monoclonal antibodies and its applications. The hybridoma cell line includes PS-8, classified as Hybridoma cell line PS-8. The accession number for PS-8 is CCTCC NO: C2024144, the accession date is May 10, 2024, and the depositary institution is the China Center for Type Culture Collection (CCTCC), located at Wuhan University, No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province. The hybridoma cell line provided by this invention can stably secrete anti-polystyrene monoclonal antibodies with high titer, good specificity, and high sensitivity, making it suitable for detection in reagent kits and possessing potential application value.

The invention mainly relates to a bovine rotavirus inactivated vaccine and a preparation method thereof, and according to the preparation method of the bovine rotavirus inactivated vaccine, ultrasonic emulsification conditions are as follows: the ultrasonic frequency is 24-28 kHz, the power density is controlled within the range of 0.6-0.8 W / cm, the single pulse time is 8-12 seconds, the ultrasonic time is 60-120 seconds, ultrasonic emulsification is carried out in a refrigerant bath at the temperature of 2-5 DEG C, the temperature fluctuation is + / -0.5 DEG C, and the ultrasonic time is 60-120 seconds. The virus content in the inactivated vaccine is greater than or equal to 5 * 10 < 5.0 > TCID50 / ml, and the neutralizing antibody titer within 21-49 days after secondary immunization is greater than or equal to 900. The prepared bovine rotavirus inactivated vaccine is subjected to ultrasonic emulsification, a generated neutralizing antibody can completely neutralize an RVA / Bovine-tc / CHN / SHH2023001 / 2023 / G10P [11] virus strain, the titer is high (the titer can reach 1700 or above at most), the duration time is long, the G10P [11] type bovine rotavirus is the most common virus infected in a dairy cow group, and the G10P [11] type bovine rotavirus can be used for preparing the vaccine. Therefore, the vaccine can be used as an alternative vaccine for preventing calves from being infected with bovine rotavirus.

The application discloses an anti-human TRPS1 monoclonal antibody and a preparation method and application thereof, and belongs to the technical field of immunology. The anti-human TRPS1 monoclonal antibody provided by the application comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences as shown in SEQ ID NO. 1-3, and VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences as shown in SEQ ID NO. 4-6. The nucleotide sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody, an expression cassette containing the nucleotide sequences, an expression vector, a recombinant cell and a recombinant bacterium are also provided. Therefore, the monoclonal antibody can be prepared by using genetic engineering technology, and the risk factors in the production and storage process of the traditional monoclonal antibody can be avoided. The monoclonal antibody prepared by the application has stable properties, high experimental repeatability and high titer, and has good specificity and affinity to the TRPS1 protein.

This invention discloses a broad-spectrum Staphylococcus aureus bacteriophage, SapYZUbeta, and its applications. This bacteriophage has been deposited at the China Center for Type Culture Collection (CCTCC) on May 16, 2022, with accession number CCTCC NO: M 2022629. Identification revealed that the full-length gene of this bacteriophage is 17,790 bp, and it does not contain tRNAs or genes associated with lysogenicity, virulence, or antibiotic resistance. This genetic background confirms the safety of this bacteriophage for use against foodborne pathogens and for bacteriophage therapy. Furthermore, the bacteriophage exhibits a high titer of 1.9 × 10⁻⁶. 9 The phage, with a concentration of PFU / mL, exhibits stable activity within a pH range of 3–12 and a temperature range of -80–60°C, and can be applied to various matrices. The phage provided by this invention can lyse multidrug-resistant wild-type strains isolated from different regions, including MRSA and MSSA, and is characterized by a broad lysis spectrum and high lysis efficiency.

The invention discloses a Nipah virus F protein monoclonal antibody and application thereof, the antibody comprises an antibody 2D12 and an antibody 3B10, and the Nipah virus F protein monoclonal antibody is prepared from Nipah virus F protein immunogen. The specific anti-Nipah virus F protein monoclonal antibody pair is prepared and detected, the monoclonal antibody pair can be specifically combined with the Nipah virus F protein, is high in titer and good in affinity and has neutralizing activity, and meanwhile, the detection kit prepared on the basis of the antibody pair can effectively carry out Nipah virus detection; and technical support can be provided for treatment, epidemiological monitoring and diagnosis of Nipah virus infection.